 |
|
Anemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones
September 18, 2009(WASHINGTON) - Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells). While certain treatments can help manage the symptoms of anemia, some studies have suggested that they may lead to complications. A new study, however, demonstrates that MDS patients with anemia may benefit from treatment with an erythropoietin (EPO)-based regimen plus supportive care without added complications as compared with those receiving supportive care alone. The study will appear in the September 17 issue of Blood, the official journal of the American Society of Hematology.
The phase III prospective, randomized trial, conducted by research teams of the Eastern Cooperative Oncology Group, was designed to evaluate the efficacy and safety of EPO with or without myeloid growth factor treatment (G-CSF, or granulocyte colony-stimulating factor) and supportive care (SC) with red blood cell transfusions for patients with early-stage MDS (n=53), in comparison to supportive care alone (n=57).
For the study, the researchers followed MDS treatment and dosing guidelines recommended by the National Comprehensive Cancer Network, which include managing anemia with erythropoiesis-stimulating agents (ESAs) such as EPO. EPO is a drug that imitates the action of the hormone erythropoietin, which stimulates the body to produce more red blood cells. Generally, therapy with G-CSF interacts with EPO treatment synergistically to improve erythroid (red blood cell) responses, especially in MDS patients that do not respond to EPO alone.
"EPO is a recommended treatment for MDS, but the combination with G-CSF and supportive care required comparative studies in this patient population," according to lead study author Peter Greenberg, MD, Professor of Medicine, Stanford University Cancer Center. "Our goal was to manage anemia while not increasing the risk of transformation to leukemia, and we undertook this study to understand if this combination might be successfully utilized in these patients."
The results of the study proved successful for this group of patients with lower-risk MDS and anemia. After the first course of therapy, 36 percent of patients in the EPO arm responded to treatment, compared with only 9.6 percent in the SC alone arm. After subsequent courses, 47 percent responded in the EPO arm. Researchers then followed both patient groups for a median of 5.8 years to determine their long-term response to treatment. Responders to EPO experienced increased survival in comparison to the non-responders (5.5 vs. 2.3 years) and significantly improved physical, emotional, and functional well-being, reduced fatigue, and improved overall quality of life. The research team otherwise found no statistically significant differences in overall survival of patients between the EPO and SC arms (3.1 vs. 2.6 years) or the incidence of transformation to AML (7.5 vs. 10.5 percent of patients, respectively), suggesting long-term safety of the EPO treatment regimen.
The study results also indicated that the combination of EPO plus G-CSF was beneficial for patients who either did not respond initially to EPO or who experienced a delayed response. Furthermore, higher doses of EPO seemed to prove valuable for a proportion of patients who initially failed to respond. Importantly, the outcomes suggested long-term tolerance to the treatment combination, with a low overall incidence of adverse events. Specifically, the researchers found no significant treatment-related increase in incidence of either cardiovascular or thrombotic (clotting) events or transformation to AML in the patients who received EPO alone or with G-CSF, as compared with those in the SC arm.
Recently, the FDA has issued alerts regarding the use of ESAs, noting increased mortality, possible tumor promotion, and thromboembolic events that have been observed in some studies of non-MDS patients receiving ESAs. However, other studies of patients with solid tumors receiving chemotherapy did not demonstrate an adverse effect of ESAs on survival.
"We believe the data suggest that the negative effects of cytokines, like ESAs, demonstrated in some studies of other diseases may relate to biologic and clinical features or the specific treatments associated with the differing disorders studied," said Dr. Greenberg. "Findings from this study demonstrate the relative safety and efficacy of EPO plus G-CSF for treating anemic lower-risk MDS patients and may be considered as part of future treatment recommendations for the use of this class of therapies."
Additional links:
* Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996), Blood First Edition Paper, prepublished online June 29, 2009
* American Society of Hematology/American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin
* ASH Model Policy on Indications for ESA Treatment for Patients with MDS
* Video and General Information on Anemia on Blood: The Vital Connection
Reporters who wish to receive a copy of the study or arrange an interview with Dr. Greenberg may contact Patrick Irelan at 202-776-0544 or pirelan@hematology.org.
The American Society of Hematology (www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. ASH provides Blood: The Vital Connection (www.bloodthevitalconnection.org), a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. It features hematologist-approved information about these common blood conditions including risk factors, preventive measures, and treatment options.
Blood, the official journal of ASH, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers weekly and is available in print and online at www.bloodjournal.org.
The American Society of Hematology
"EPO is a recommended treatment for MDS, but the combination with G-CSF and supportive care required comparative studies in this patient population," according to lead study author Peter Greenberg, MD, Professor of Medicine, Stanford University Cancer Center. "Our goal was to manage anemia while not increasing the risk of transformation to leukemia, and we undertook this study to understand if this combination might be successfully utilized in these patients."
The results of the study proved successful for this group of patients with lower-risk MDS and anemia. After the first course of therapy, 36 percent of patients in the EPO arm responded to treatment, compared with only 9.6 percent in the SC alone arm. After subsequent courses, 47 percent responded in the EPO arm. Researchers then followed both patient groups for a median of 5.8 years to determine their long-term response to treatment. Responders to EPO experienced increased survival in comparison to the non-responders (5.5 vs. 2.3 years) and significantly improved physical, emotional, and functional well-being, reduced fatigue, and improved overall quality of life. The research team otherwise found no statistically significant differences in overall survival of patients between the EPO and SC arms (3.1 vs. 2.6 years) or the incidence of transformation to AML (7.5 vs. 10.5 percent of patients, respectively), suggesting long-term safety of the EPO treatment regimen.
The study results also indicated that the combination of EPO plus G-CSF was beneficial for patients who either did not respond initially to EPO or who experienced a delayed response. Furthermore, higher doses of EPO seemed to prove valuable for a proportion of patients who initially failed to respond. Importantly, the outcomes suggested long-term tolerance to the treatment combination, with a low overall incidence of adverse events. Specifically, the researchers found no significant treatment-related increase in incidence of either cardiovascular or thrombotic (clotting) events or transformation to AML in the patients who received EPO alone or with G-CSF, as compared with those in the SC arm.
Recently, the FDA has issued alerts regarding the use of ESAs, noting increased mortality, possible tumor promotion, and thromboembolic events that have been observed in some studies of non-MDS patients receiving ESAs. However, other studies of patients with solid tumors receiving chemotherapy did not demonstrate an adverse effect of ESAs on survival.
"We believe the data suggest that the negative effects of cytokines, like ESAs, demonstrated in some studies of other diseases may relate to biologic and clinical features or the specific treatments associated with the differing disorders studied," said Dr. Greenberg. "Findings from this study demonstrate the relative safety and efficacy of EPO plus G-CSF for treating anemic lower-risk MDS patients and may be considered as part of future treatment recommendations for the use of this class of therapies."
Additional links:
* Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996), Blood First Edition Paper, prepublished online June 29, 2009
* American Society of Hematology/American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin
* ASH Model Policy on Indications for ESA Treatment for Patients with MDS
* Video and General Information on Anemia on Blood: The Vital Connection
Reporters who wish to receive a copy of the study or arrange an interview with Dr. Greenberg may contact Patrick Irelan at 202-776-0544 or pirelan@hematology.org.
The American Society of Hematology (www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. ASH provides Blood: The Vital Connection (www.bloodthevitalconnection.org), a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. It features hematologist-approved information about these common blood conditions including risk factors, preventive measures, and treatment options.
Blood, the official journal of ASH, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers weekly and is available in print and online at www.bloodjournal.org.
The American Society of Hematology
Anemia Current Events and Anemia News RSSLet them eat snail
A nutritionist in Nigeria says that malnutrition and iron deficiency in schoolchildren could be reduced in her country by baking up snail pie.
Drugs to treat anemia in cancer patients linked to thromboembolism
Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center.
Mortality Rates Reduced among Children Whose Mothers Received Iron-folic Acid Supplements
Offspring whose mothers had been supplemented with iron-folic acid during pregnancy had dramatically reduced mortality through age 7, according to researchers at the Johns Hopkins Bloomberg School of Public Health.
Experts unveil new CVD guidelines and position papers
Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.
Mayo Clinic study shows people with heart devices can 'digest' advanced diagnostic technology safely
A new Mayo Clinic study suggests that video capsule endoscopy (CE), a procedure that uses wireless technology in diagnosing intestinal disease, is safe for patients with heart devices.
Common weed could provide clues on aging and cancer
A common weed and human cancer cells could provide some very uncommon details about DNA structure and its relationship with telomeres and how they affect cellular aging and cancer, according to a team led by scientists from Texas A&M University and the University of Cincinnati (UC).
Designer molecule detects tiny amounts of cyanide, then glows
A small molecule designed to detect cyanide in water samples works quickly, is easy to use, and glows under ultraviolet or "black" light.
American Dietetic Association supports IOM recommendations on school meal programs
The American Dietetic Association welcomes a report issued Wednesday, October 21, by the Institute of Medicine encouraging federal school meal programs to adopt standards that increase the nutrition content and limit the calories in meals served to schoolchildren.
Better blood screening process needed to prevent babesiosis transmission
Babesiosis is a potentially dangerous parasitic disease transmitted by ticks and is common in the Northeast and the upper Midwest. Babesia lives inside of red blood cells, meaning it can also be transmitted through a blood transfusion from an infected but otherwise asymptomatic blood donor.
Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.
More Anemia Current Events and Anemia News Articles
 |
The Iron Disorders Institute Guide to Anemia by Cheryl Garrison (Author) More than 2 billion people worldwide have some form of anemia. Even so, the condition is greatly misunderstood and often improperly treated. The Iron Disorders Institute Guide to Anemia contains everything a patient needs to know about the different forms of anemia, symptoms, treatment, and diet. It provides patients and family members with everything they need to be proactive with their physicians, including information about what doctors must do to differentiate between different causes and how each cause is treated. |
 |
Anemia in Women: Self-Help and Treatment by M.D. Joan Gomez (Author) Many women are unaware that they have anemia. Its symptoms — fatigue, weakness, shortness of breath, headaches, and poor concentration — are often attributed to stress rather than iron deficiency. Using case studies, Joan Gomez discusses the prevention and treatment of anemia during childhood, adolescence, and menopause. |
 |
Nature's Plus - Hema-Plex, 30 tablets by Nature's Plus |
 |
Understanding Anemia (Understanding Sickness & Health Series) by M.D., Ed Uthman (Author) Each year thousands are told they suffer from anemia, but most have only a vague understanding of the condition. In fact, "anemia" is a generic term that includes myriad specific diseases, each of which has its own story regarding cause, manifestations, and treatments. Understanding Anemia gently builds upon elementary knowledge of biology to provide the general reader with a fairly sophisticated understanding of the various causes of anemia, of the methods used to make diagnoses, and of the principles of treatment. The book begins with a definition of anemia and a brief history of the scientific study of blood. It explains how the doctor makes the diagnosis and details the main types of anemia. Since the different conditions result from the failure of... |
 |
Anemias and Other Red Cell Disorders by Kenneth Bridges (Author), Howard A. Pearson (Author) The first comprehensive, yet concise, clinical guide to the full spectrum of anemias Anemias and Other Red Cell Disorders is the first resource to provide a practical diagnostic/treatment framework for identifying and successfully managing acute, congenital, and chronic anemias, and other red blood cell disorders. With its broad scope, easy-to-navigate format, and ready-to-apply diagnostic and treatment strategies, this is the most accessible - and essential - guide to anemias and related diseases ever published. Features A complete top-to-bottom review of anemias, written with the non-specialist in mind Logical chapter organization based on the clinical features that prompt the initial encounter between doctor and patient Discussions... |
 |
Aenima by Tool No Description Available Track: 10: Die Eier Von Satan,Track: 11: Pushit,Track: 12: Cesaro Summability,Track: 13: Aenema,Track: 14: (-) Ions,Track: 15: Third Eye,Track: 1: Stinkfist,Track: 2: Eulogy,Track: 3: H.,Track: 4: Useful Idiot,Track: 5: Forty Six And 2,Track: 6: Message To Harry Manback,Track: 7: Hooker With A Penis,Track: 8: Intermission,Track: 9: Jimmy Media Type: CD Artist: TOOL Title: AENIMA Street Release Date: 10/01/1996 |
 |
Heavy Menstrual Flow and Anemia: Self Help Book by Susan M. Lark (Author) Most women have experienced unusually heavy menstrual bleeding at one time or another in their lives. But for millions of American women, heavy menstrual flow and the debilitating effects of anemia are chronic problems. Because it isn't enough to treat only the symptoms, Dr. Lark examines the underlying causes associated with these conditions, analyzes the risk factors for different groups of women, and presents a comprehensive self-assessment program. She discusses the vital roles of diet and exercise in coping with heavy menstrual flow and anemia, as well as the most current medical treatment and drug therapies available. |
 |
Biosafe Anemia Meter, Red (1 test) by Biosafe The Anemia Meter is the world's first single use rapid response Anemia Device! The test provides you with an accurate, convenient, and inexpensive way to test for possible anemia in the comfort and safety of your home or office. Low hemoglobin levels are associated with extreme weakness, fatigue, shortness of breath, dizziness, depression, rapid heart beat, and/or pale skin. People over 65, those who have had recent surgery, and HIV/AIDS patients are at increased risk. Additionally, people who have kidney disease, diabetes, rheumatoid arthritis, cancer, or heart disease should check their hemoglobin level regularly. The specimen collection process is quick, easy and virtually painless. Using the special lancet (included with the BIOSAFE Anemia Meter), one or more drops of blood are taken... |
 |
Pale Faces: The Masks of Anemia (A BLP Pathography) by Charles Bardes (Author) "Charles Bardes' meditations on medicine . . . are beautifully-transparently-written, deeply informed . . . and they carry surprise."-Sven Birkerts, author of Reading Life and The Gutenberg Elegies Whether mild or deadly, anemia affects an essential body fluid: blood. Probing deeply into this illness as metaphor, Charles L. Bardes explores the impact of both science and culture on its treatment across the ages. His innovative "life" of this condition ranges widely through history, art, literature, and clinical practice to examine how the way doctors think influences the practice of medicine. |
 |
Cancer Patients and Anemia Part of the award winning public television series Healthy Body/Healthy Mind. Anemia (an abnormally low number of red blood cells) is a common condition in cancer patients that may occur either as a direct result of the cancer or as a side effect of the cancer treatment. Chemotherapy, radiation therapy, and blood loss during surgery are all common causes of anemia in cancer patients. But, as you'll see in this program, anemia can be successfully treated, and patients can go on to beat their cancers and live healthy lives. |
| © 2009 BrightSurf.com |